All

Brexit Watch

On 23 June 2016, the United Kingdom (UK) cast its historic vote to leave the European Union (EU), setting into motion the end of its 43-year membership. The UK formally notified its intention to withdraw from the EU on 29 March 2017, starting a two-year negotiation on the terms of withdrawal and future cooperation.

During this period of uncertainty, Arnold & Porter will monitor the latest Brexit developments as they unfold. The goal—to provide you with our best assessments on the likely legal consequences across a range of sectors, when relevant. If you have any specific questions relating to Brexit's impact on your business or industry, please contact our attorneys, as listed below.

Resource

Key Contacts

Corporate Agreements and Commercial Contracts

Jeremy Willcocks

Data Protection

Henry Clinton-Davis

Dispute Resolution

Hilton Mervis

Employment Law

Henry Clinton-Davis

Intellectual Property

Dr. Beatriz San Martin

Life Sciences

Ian Dodds-Smith  Lincoln Tsang  Adela Williams

Perspectives

January 8, 2021
The EU and UK Trade and Co-Operation Agreement: Implications for Life Sciences Companies
Advisory
December 17, 2020
End of Brexit Transition Period: Exhaustion of Intellectual Property Rights and Parallel Trade in the UK and EU
Bioslice Blog
December 10, 2020
EU Clinical Trials Bootcamp: Focus on Agreements
Arnold & Porter and Future Pharma Forum Webinar
December 3, 2020
UK MHRA Consultation on Real-World Evidence
BioSlice blog
September 11, 2020
Merger Control in the UK—Three and a Half Things You Need to Know
Advisory
Tuesday, June 23, 2020
Public International Law in the UK, Post-Brexit
Young Public International Law Group (YPILG) and Arnold & Porter Webinar
June 22, 2020
EU Clinical Trials Regulation: The Clinical Trials Information System expected to go live by December 2021, according to the EMA
BioSlice Blog
March 20, 2020
What Might Whistleblower Protections Look Like For UK Pharma Post-Brexit?
The Pink Sheet
February 20, 2020
UK government publishes new draft legislation on medicines and medical devices
BioSlice Blog
January 30, 2020
Brexit and Merger Control
Advisory
November 27, 2019
Latest Developments in the Transparency Activities of the European Medicines Agency
BioSlice Blog
September 25, 2019
Brexit and Merger Control
Advisory
August 8, 2019
Will the government waive competition law if there's no deal?
CapX
July 30, 2019
Update on the Implementation of the European Medical Devices Regulation and In Vitro Diagnostics Regulation
Advisory
March 21, 2019
SEC Division of Corporation Finance Director Discusses Brexit and Sustainability Disclosures
Advisory
March 19, 2019
Competition Litigation After Brexit
Advisory
March 13, 2019
Impact of UK's Temporary Tariff Regime on Life Sciences
BioSlice Blog
February 21, 2019
Frustrated by Brexit?
BioSlice Blog
January 10, 2019
MHRA's updated guidance on a hard-Brexit
BioSlice Blog
December 11, 2018
Brexhaustion: IP Rights and Exhaustion Post-Brexit
BioSlice Blog
October 2, 2018
Hard or Soft Brexit: What Happens to Merger Reviews?
Advisory
September 12, 2018
MHRA guidance on no-deal Brexit
BioSlice Blog
August 2, 2018
MedTech Europe requests extension to the transition period for the MDR
BioSlice Blog
July 13, 2018
UK Government's Brexit White Paper
BioSlice Blog
July 13, 2018
EMA publishes results of study on Brexit preparedness
BioSlice Blog
June 8, 2017
Brexit and the Impact on Clinical Research
Clinical Trials Arena
September 20, 2016
The European Union's E-Privacy Revamp: What is Being Proposed?
Advisory
September 13, 2016
Brexit Watch Resource
Arnold & Porter Resource
June 29, 2016
Brexit—What We Know
Advisory
June 27, 2016
How Brexit May Affect Public Procurement
Advisory
May 26, 2016
Brexit and the Implications for the Life Sciences Industry
Advisory
Subscribe
Subscribe Link

Email Disclaimer

Reject Accept